Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037028 | 0.87 | ALDH1A1 (0.38) | ALDH1A1LMNABCHECYP2D6ACHE | |
| SCHEMBL2914178 | 0.81 | HRH3 (0.40) | ALDH1A1CYP2D6SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4038774 | 0.77 | — | — | |
| SCHEMBL4042911 | 0.72 | HPGD (0.32) | — | |
| SCHEMBL3594071 | 0.71 | HPGD (0.32) | — | |
| SCHEMBL4821997 | 0.70 | — | — | |
| SCHEMBL4036102 | 0.70 | HPGD (0.33) | — | |
| SCHEMBL4035871 | 0.69 | SIGMAR1 (0.50) | ALDH1A1LMNACYP2D6SIGMAR1OPRL1 | |
| SCHEMBL8931179 | 0.69 | SIGMAR1 (0.44) | LMNAACHETMEM97SIGMAR1 | |
| SCHEMBL4821994 | 0.68 | TACR1 (0.35) | ALDH1A1BCHEACHETMEM97MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531545-B2 | 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-0988289-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998055454-A2 | BENZOFURANS AND BENZOTHOPHENES AS SUPPRESSORS OF NEURODEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | ALDH1A1 311/4885LMNA 1890/4885BCHE 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.